CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 86 enrolled
Drug / intervention
Exparel +1 moredrug
Likely dose
Exparel 30mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03080142
NCT03080142Phase 4Completed
CompareCT.gov

Transversus Abdominus Plane (TAP) Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery: A Prospective Randomized Control Trial

University of California, Davis·interventional·Posted Mar 15, 2017·Updated Apr 27, 2021

In Brief

A Phase 4 clinical trial evaluating Exparel and Ropivacaine for Colorectal Surgery and TAP Blocks. Completed, enrolled 86 participants across 1 site.

Detailed Summary

This is a prospective randomized study designed to compare the pain control from a single shot of liposomal bupivacaine (Exparel) against transversus abominus plane (TAP) catheters with ropivicaine bolus in patients undergoing elective colorectal surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Surgery, TAP Blocks
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 15, 2017
Enrollment StartMar 1, 2017
Primary CompletionMay 29, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.3 years ago

Interventions

Expareldrug

Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.

Ropivacainedrug

Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.